Daniel Haders
Professional Experience
Dr. Haders has 20+ years of experience in healthcare as a scientist, entrepreneur, advisor, investor & BoD member.
He is currently the Co-Founder & CEO of Model Medicines, an AI-driven, human health company using AI to model all of chemistry and human biology. The company has built a pipeline of novel acting therapeutics, including the potential best-in-class, first-in-class MDL-001. Model Medicines has raised over $14M to date with backing from investors including 8VC, Friedman Bioventures, Irving Ventures, ParticleX & Thermopolis Partners.
Prior to co-founding Model Medicines, Daniel launched the Nex Cubed Digital Health Accelerator. Here, Daniel built an early-stage investment portfolio of 25+ Digital Healthcare companies with an enterprise value of over $250M, investment results that would place the portfolio in the top decile. The accelerator has been named one of the “Top Ten Global Digital Health Accelerators” & “The Best Accelerators & Incubators for FemTech Startups”. In addition, Nex Cubed Digital Health has run partnered accelerators w/ numerous countries & publicly traded companies incl’ing Enterprise Singapore, Canada and GE Healthcare.
He is an Operating Partner at Sway Ventures, where he advises on the firm’s Digital Health portfolio. Here Dr. Haders served as Board Observer at AppliedVR, a VR digital therapeutic company, backed by investors including F-Prime, Jazz, SVB & JJDC, which was granted break though device designation and cleared by the FDA in 2022. Other investments include MedCrypt, which recently closed its Series B with co-investors including Dexcom, JJDC, Intuitive Ventures & Section 32.
Dr. Haders is a member of the Board at Regenexx & Consano Biologics, has served as a Faculty Member & Member of the Advisory Committee of the UCSD, Digital Health Certificate Program & is a Member of the BioMedX Oversight Committee at Columbia University Technology Ventures.
Prior to current roles, he held positions from Fellow to Senior Scientist to Co-Founder/CEO in the fields of medical devices, pharmaceuticals & nano-drug delivery. At LuxBio, Daniel helped develop LX214 from concept through a successful Phase I study. The LX214 program was further developed clinically by Sun Pharma & gained FDA approval under the name CEQUA in 2018.
Dr. Haders holds a BS & PhD in Biomedical Eng. & has been awarded multiple Fellowships for scientific research incl a National Science Foundation IGERT Fellowship & a Dept. of Ed. GAANN Fellowship in Molecular, Cellular and Nanosystems BioEng.